Martina’s experiments suggest that TREM2 deficiency may promote increased T cell activation and may enhance responsiveness to anti-PD-1 checkpoint blockade, and treatment with anti-TREM2 mAb curbed tumor growth and fostered regression when combined with anti-PD-1 (172). The gene discussed is TREM2; the disease is neoplasm.